Corcept Therapeutics Incorporated

NASDAQ:CORT

Biotechnology

Healthcare
$67.79 -2.34%

-$1.96 today

Market cap
$7.42B
Beta
0.50
P/E (TTM)
178.2
EPS (TTM)
$0.46
52W Low $28.66High $91.00

Volume 0.74M

Average 1.41M

CORT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Corcept Therapeutics IncorporatedNASDAQ: CORT

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense remains negative

Q2 FY2026 income tax expense was -$2.94M, compared with -$3.46M a year earlier. Trailing-twelve-month income tax expense was -$35.26M.

Context

  • Income tax expense amounted to 4.4% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -$2.94M or moves back toward the trailing-twelve-month quarterly average of -$8.82M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.94M+78.2% QoQ
Last fiscal yearDec 2025
-$33.19M-263.6% YoY
LTMJun 2026
-$35.26M-373.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.8%——
1 year-263.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(33.19M) USD
Year-over-year change
-263.6%

Income Tax Expense vs competitors

How CORT compares with its peers on the latest reported figures

  • CORT's LTM Jun 2026 income tax expense of -$35.26M is the lowest of the 3 companies compared; the peer median is $0.
  • Income tax expense amounts to 4.2% of revenue for CORT.
CORT Competitors Peer median
Income Tax Expense for CORT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 ———
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 ———
CORTCorcept Therapeutics IncorporatedLTM Jun 2026-$35.26M -373.8%—4.2%
Peer median (excluding CORT) $0———

Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue365.98M401.86M482.38M675.04M761.41M
Cost of Revenue5.28M5.39M6.48M10.88M12.98M
Gross Profit360.7M396.47M475.89M664.16M748.43M
Gross Margin98.6%98.7%98.7%98.4%98.3%
Research & Development113.86M130.99M184.35M246.89M254.91M
Selling, General & Admin122.36M152.85M184.26M280.32M448.73M
Operating Expenses236.22M283.84M368.61M527.21M703.63M
Depreciation & Amortization3.07M3.45M2.36M1.34M1.89M
EBITDA127.95M119.64M126.92M162.83M68.35M
EBITDA Margin35.0%29.8%26.3%24.1%9.0%
Operating Income124.48M112.63M107.28M136.95M44.8M
Operating Margin34.0%28.0%22.2%20.3%5.9%
Interest Income529K3.56M17.28M24.54M21.67M
Interest Expense00000
Other Income / Expenses529K3.56M17.28M24.54M21.67M
Income Before Tax125.01M116.19M124.56M161.49M66.46M
Pre-Tax Margin34.2%28.9%25.8%23.9%8.7%
Income Tax Expense12.49M14.77M18.42M20.28M(33.19M)
Net Income112.51M101.42M106.14M139.73M99.65M
Net Margin30.7%25.2%22.0%20.7%13.1%
EPS (Basic)0.970.951.021.350.95
EPS (Diluted)0.890.870.941.230.82
Weighted Avg Shares115.65M106.79M103.56M103.23M103.86M
Weighted Avg Shares (Diluted)125.96M115.97M111.74M113.48M119.99M

Corcept Therapeutics Incorporated

NASDAQ:CORT

Intrinsic Alpha fair value

Locked

Current Price

$67.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.